<DOC>
	<DOC>NCT01622777</DOC>
	<brief_summary>To evaluate the impact of oral rosuvastatin in diabetic polyneuropathy, and the role of lipid peroxidation and nerve growth factor.</brief_summary>
	<brief_title>The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus Glycated hemoglobin &lt;12.0% Signing of informed consent Presence of an abnormality of nerve conduction study Symptoms and signs of diabetic polyneuropathy Pregnancy and lactation Foot ulcers Treatment with statins Antioxidant drug and/or supplements one month previous to enrolment Inability to mobilize Renal and/or hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Rosuvastatin</keyword>
	<keyword>Diabetic polyneuropathy</keyword>
	<keyword>Nerve conduction</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Nerve growth factor</keyword>
</DOC>